ArticleFrontiers in oncology2026
Comparison of gene mutations of liver metastases to the primary tumor in colorectal cancer: lessons from a small cohort.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Upfront molecular diagnostics are used to characterize genetic features of colorectal cancer, guiding therapy. Since colorectal cancer is usually surgically resected, these samples are used for such characterizations. The extent to which liver metastases maintain the genetic profile of the primary tumor is a key question. Methods: Here, we used a small six-case pretreatment colorectal cancer cohort where targeted next-generation sequencing (NGS) was employed to compare liver metastases to the primary tumors. Results: We found, similar to previous reports, that the major genetic drivers are maintained in the liver metastases; however, changes at this level can still be detected. We also observed that in the majority of cases, the genetic profile of the primary tumor is partially or completely lost in liver metastases. On the other hand, we detected the metastasis-selective emergence of ABL1, HER2, RET, KIT, KDR, and VHL mutations. Discussion: Although our study is only hypothesis-generating, these data support the view that genetic analysis of colorectal cancer liver metastases may identify novel alterations compared to the primary tumors, which can be clinically exploited during disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.